References
- Horowski R., Sastre M. Clinical effects of the neurotropic selective phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Current Therapeutic Research 1985; 38: 23–29
- Krause W., Kühne G. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 1988; 18: 561–571
- Krause W., Kühne G. High-performance liquid chromatographic procedure for specificity testing of radioimmunoassays: rolipram. Journal of Chromatography 1992; 573: 303–308
- Krause W., Kühne G., Jakobs U., Hoyer G.-A. Biotransformation of the antidepressant D,L-rolipram. I. Isolation and identification of metabolites. Drug Metabolism and Disposition 1993, in press
- Krause W., Kühne G., Matthes H. Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica 1989; 19: 683–692
- Krause W., Kühne G., Sauerbrey N. Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers. European Journal of Clinical Pharmacology 1990; 38: 71–75
- Laemmel K., Sastre M. Rolipram as an antidepressant. World Congress of Psychiatry, Vienna 1983; 677, Abstract VII.
- Przegalinski E., Bigajska K., Lewandowska A. The influence of rolipram in the central serotoninergic system. Pharmacopsychiatria 1981; 14: 162–166
- Schultz J. E., Schmidt B. H. Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes β-adrenoceptor subsensitivity in rat cerebral cortex. Naunyn-Schmiedeberg's Archiv der Pharmakologie 1986; 333: 23–30
- Wachtel H. Selective adenosine cyclic 3′-5′-monophosphate phosphodiesterase inhibitors—a novel class of antidepressant? Abstract, 13th Congress Colloquium International Neuropsychopharmacology. Jerusalem 1982a; 740
- Wachtel H. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology 1982b; 77: 309–316
- Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′-5′-monophosphate phosphodiesterase inhibitors. Neuropsychopharmacology 1983; 22: 267–272
- Zeller E., Stief H. J., Pflug B. Sastre-y-Hernandez., Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatria 1984; 17: 188–190